cadth 2015 b7 crosbie
TRANSCRIPT
Scientific Advice
ProgramSupporting the Generation of High Quality Evidence
David Crosbie, Program LeadScientific Advice
2
About the Scientific Advice Program
Voluntary, fee-for-service consultation for pharmaceutical companies
Advice on early drug development plans from a health technology assessment perspective
Advice at an early point in the drug development process
3
About the Scientific Advice Program
Independence
Confidentiality
4
www.cadth.ca/scientificadvice
5
6
7
8
9
Eligibility
New drug products
Existing drug products with new indications
Drugs for rare diseases
Subsequent entry biologics (SEBs)
Oncology products
10
Patient Involvement
11
Benefits for patients
Early input in drug development process
Stronger recommendations based on better evidence
12
Benefits for pharmaceutical companies
Reduced uncertainty
Test new development strategies
Advice in context
13
Benefits for CADTH
Influence evidence generated
Early knowledge of methodologies and approaches
15